Quality and Patient Safety
Brooke Barlow, PharmD, BCCCP
Medical Science Liaison
Memorial Hermann The Woodlands Medical Center
Spring, Texas
Ensuring safe, effective, and timely care for patients with acute ischemic stroke can decrease stroke-related morbidity and mortality. Tenecteplase has emerged as an alternative to alteplase for thrombolytic therapy in patients with acute ischemic stroke. Evidence suggests potential improved outcomes in some patient populations. Scientific evidence, operational logistics, and cost considerations can guide institutional conversations when determining preferred formulary thrombolytic therapy. This session focuses on a multiprofessional approach to implementing an alteplase-to-tenecteplase protocol. Speakers will address the rationale for a fibrinolytic switch, clinical considerations, patient outcomes, and the communication and team-based approach essential to the successful conversion of a high-risk medication. Safety considerations in prescribing, ordering, administration, and monitoring will be covered. This session will use a flipped classroom format. The focus will be on physician and pharmacist roles before, during, and after transition. Speakers will discuss cases to emphasize important considerations during the transition and the key players essential to ensuring success. Speakers will engage audience members to solicit thoughts and allow for questions.